Label: CORTI-SAV- hydrocortisone and iodoquinol cream

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated July 15, 2021

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Contains hydrocortisone 1% and iodoquinol 1% in a greaseless cream of cetyl alcohol, glyceryl monostearate SE, isopropyl myristate, lanolin alcohol, mineral oil, polyoxyl 40 stearate, polysorbate 20, polysorbate 60, propylene glycol, purified water, sorbic acid, and sorbitan monostearate.

    Paraben Free.

    Chemically, hydrocortisone is [Pregn-4-ene-3, 20-dione, 11, 17, 21-trihydroxy-, (11β)-] with the molecular formula C 21H 30O 5) and is represented by the following structural formula:

    Chemical Structure

    and iodoquinol, 5, 7-diiodo-8-quinolinol (C 9H 5I 2NO) is represented by the following structural formula:

    Chemical Structure

    Hydrocortisone is an anti-inflammatory and antipruritic agent, while iodoquinol is an antifungal and antibacterial agent.

  • CLINICAL PHARMACOLOGY

    Hydrocortisone has an anti-inflammatory, antipruritic and vasoconstrictive properties. While the mechanism of anti-inflammatory activity is unclear, there is evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and the therapeutic efficacy in humans lodoquinol has both antifungal and antibacterial properties.

    Pharmacokinetics

    The extent of the percutaneous absorption of topical steroids is determined by many factors including the vehicle, the integrity of the epidermal barrier and the use of occlusive dressings. Hydrocortisone can be absorbed from normal intact skin. Inflammation and/or other inflammatory disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Once absorbed through the skin, hydrocortisone is metabolized in the liver and most body tissue to hydrogeneted and degraded forms such as tetrahydrocortisone and tetrahydrocortisol. These are excreted in the urine, mainly conjugated as glucuronides, together with a very small proportion of unchanged hydrocortisone. There are no data available regarding the percutaneous absorption of iodoquinol; however, following oral administration, 3-5% of the dose was recovered in the urine as glucuronide.

  • INDICATIONS

    Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: "Possibly" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation.

  • CONTRAINDICATIONS

    This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product.

  • WARNING

    FOR EXTERNAL USE ONLY.

  • PRECAUTIONS

    NOT FOR OPHTHALMIC USE.

    KEEP OUT OF REACH OF CHILDREN.

    Avoid contact with eyes, lips and mucous membranes.

    Information for Patients

    If irritation develops, the use of this product should be discontinued and appropriate therapy instituted. Staining of the skin, hair and fabrics may occur. Not intended for the use on infants or under diapers of occlusive dressings. If extensive areas are treated or if the occlusive dressing technique is used, the possibility exists of increased systemic absorption of the corticosteroid, and suitable precautions should be taken.

    Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity.

    Iodoquinol may be absorbed through the skin and interfere with thyroid function tests. If such tests are contemplated, wait at least one month after discontinuance of therapy to perform these tests. The ferric chloride test for phenylketonuria (PKU) can yield a false positive result if iodoquinol is present in the diaper or urine. Prolonged use may result on overgrowth of non-susceptible organisms requiring appropriate therapy.

    Carcinogenesis, Mutagenesis and Impairment of Fertility

    Long-term animal studies for carcinogenic potential have not been performed on this product to date. In vitro studies to determine mutagenicity with hydrocortisone have revealed negative results. Mutagenicity studies have not been performed with iodoquinol.

    Pregnancy

    Category C

    Animal reproduction studies have not been conducted with this product. It is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. This product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus.

    Nursing Mothers

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.

    Pediatric Use

    Safety and effectiveness in pediatric patients under the age of 12 have not been established.

  • ADVERSE REACTIONS

    The following local adverse reactions are reported infrequently with topical corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infections, skin atrophy, striae and miliaria.

  • DOSAGE AND ADMINISTRATION

    Apply to affected area 3 to 4 times daily in accordance with physician's directions.

  • STORAGE

    Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (between 59°F to 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however, such exposure should be minimized. Keep container tightly closed.

    NOTICE

    Protect from freezing and excessive heat.

  • HOW SUPPLIED

    1 oz. tubes, NDC 72336-811-30

    To report a serious adverse event or obtain product information, call 1-888-463-6332.

  • SPL UNCLASSIFIED SECTION

    Manufactured for:

    LiFsa Drugs LLC
    New Brunswick NJ 08901

  • PRINCIPAL DISPLAY PANEL

    NDC 72336-811-30

    Corti-Sav

    Hydrocortisone 1%−Iodoquinol 1% Cream

    NET WT 1 oz (28.4 g)

    LABEL
  • INGREDIENTS AND APPEARANCE
    CORTI-SAV 
    hydrocortisone and iodoquinol cream
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:72336-811
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    HYDROCORTISONE (UNII: WI4X0X7BPJ) (HYDROCORTISONE - UNII:WI4X0X7BPJ) HYDROCORTISONE10 mg  in 1 g
    IODOQUINOL (UNII: 63W7IE88K8) (IODOQUINOL - UNII:63W7IE88K8) IODOQUINOL10 mg  in 1 g
    Inactive Ingredients
    Ingredient NameStrength
    CETYL ALCOHOL (UNII: 936JST6JCN)  
    GLYCERYL STEARATE SE (UNII: FCZ5MH785I)  
    ISOPROPYL MYRISTATE (UNII: 0RE8K4LNJS)  
    LANOLIN ALCOHOLS (UNII: 884C3FA9HE)  
    MINERAL OIL (UNII: T5L8T28FGP)  
    POLYOXYL 40 STEARATE (UNII: 13A4J4NH9I)  
    POLYSORBATE 20 (UNII: 7T1F30V5YH)  
    POLYSORBATE 60 (UNII: CAL22UVI4M)  
    PROPYLENE GLYCOL (UNII: 6DC9Q167V3)  
    WATER (UNII: 059QF0KO0R)  
    SORBIC ACID (UNII: X045WJ989B)  
    SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)  
    Product Characteristics
    Coloryellow (Light yellow) Score    
    ShapeSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:72336-811-301 in 1 CARTON07/15/2021
    128.4 g in 1 TUBE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other07/15/2021
    Labeler - Lifsa Drugs LLC (081205160)